Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Australian biotech Immuron takes gut health treatment to the US market - BioPharmaDispatch
1+ hour, 35+ min ago (121+ words) Australian biotech Immuron takes gut health treatment to the US market PharmaDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an…...
Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage - BioPharmaDispatch
1+ hour, 25+ min ago (124+ words) Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage PharmaDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology company developing…...
Alterity secures option underwriting as it prepares for pivotal MSA trial
1+ week, 34+ min ago (140+ words) PharmaDispatch Alterity secures option underwriting as it prepares for pivotal MSA trial Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of…...
Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast
4+ week, 21+ hour ago (115+ words) PharmaDispatch Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast AusBiotech has unveiled the integrated program for the 2026 AusBiotech International Conference and AusMedtech Conference, bringing more than 250 speakers together across approximately 60 sessions on the Gold…...
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
1+ mon, 1+ week ago (146+ words) PharmaDispatch Helping to build Australia’s life sciences future at Brisbane’s innovation junction Professor Trent Munro, General Manager of the BRIJ, and Rebekah Cassidy, CEO of AusBiotech, spoke with BioPharmaDispatch-BPDInsights about the precinct’s contribution to how Australia’s life sciences sector is…...
The 'end of days' language is just a farcical attempt to shut down discussion
1+ mon, 2+ week ago (138+ words) PharmaDispatch The 'end of days' language is just a farcical attempt to shut down discussion There is a distinct and entirely theatrical moral posturing around debates on pharmaceutical spending and pricing. The language of sin and salvation is consistently used…...
Major brands and biosimilars feature prominently on November PBAC agenda - BioPharmaDispatch
1+ mon, 2+ week ago (133+ words) Major brands and biosimilars feature prominently on November PBAC agenda PharmaDispatch Major brands and biosimilars feature prominently on November PBAC agenda The agenda for the Pharmaceutical Benefits Advisory Committee's November 2026 meeting reveals a diverse range of submissions seeking PBS funding…...
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
1+ mon, 2+ week ago (159+ words) PharmaDispatch Bellberry and ASCEPT release checklist for 'new approach methodologies' trials Professor Andrew Wilson AO, who chaired the Scientific Advisory Committee, said, "They may not entirely replace animal studies in every case, but they can often provide richer, more human…...
Australian approval for AstraZeneca's near‑zero global warming propellant inhaler
1+ mon, 2+ week ago (128+ words) PharmaDispatch Australian approval for AstraZeneca's near‑zero global warming propellant inhaler Dr Marie Guillet, Country President of AstraZeneca Australia and New Zealand, welcomed the registration and framed it as both a clinical and environmental advance. … Novartis names Anne Harris to…...
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
2+ mon, 3+ week ago (126+ words) PharmaDispatch Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into…...